Dualitas and Roche are collaborating on the discovery of novel bispecific antibodies for I&I diseases
Dualitas will screen over 300,000 novel bispecific combinations
Advertisement
Dualitas Therapeutics, Inc. announced a research collaboration and license agreement with Roche to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases, using Dualitas' DualScreen™ Bispecific Discovery Engine. In what is believed to be one of the largest-scale bispecific discovery endeavors, Dualitas will functionally screen over 300,000 novel bispecific combinations to discover and develop bispecific antibody ("BsAb") therapeutics. Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing and commercial activities.
The collaboration will leverage Dualitas' expertise in proximity biology to develop BsAb candidates with synergistic activities that are unattainable with conventional therapeutics. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for a potential total deal value of up to $1 billion, in addition to tiered royalties.
"We are thrilled to partner with Roche on this first-of-its-kind collaboration to functionally screen and develop novel proximity BsAbs at a scale that was previously unachievable," said Forbes Huang, co-founder, chief operating officer and chief business officer of Dualitas. "Since founding Dualitas in 2023, we have established our DualScreen ™ discovery engine as the premier technology for discovering next-generation proximity BsAbs, as exemplified by our robust therapeutic pipeline entering clinic next year for I&I diseases."
"Bispecific antibodies remain central to Roche's portfolio strategy across many disease areas," said Boris L. Zaïtra, Head of Corporate Business Development at Roche. "We are committed to continue pushing the boundaries of scientific innovation in immunology and inflammation diseases that will ultimately benefit patients through external partnerships."
"This collaboration with Roche underscores the enormous potential of Dualitas' technologies to identify BsAbs that harness novel proximity mechanisms that may deliver truly differentiated results to patients," said Karim Dabbagh, Ph.D., CEO and board member of Dualitas. "Our internal pipeline of proximity engager BsAbs has already demonstrated the ability to drive amplified therapeutic effects that push the boundary of what conventional antibody therapies can achieve. This collaboration extends our therapeutic innovations while we continue to develop our internal pipeline."
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
